Methyl 2-Bromothiazole-5-Carboxylate

Addition of methyl 2-bromothiazole-5-carboxylate to a degassed 4:1 (v/v) 1,4-dioxane/water mixture containing 1.05 eq of 4-fluorophenylboronic acid, 0.8 mol% Pd(PPh₃)₄ and 2.5 eq of anhydrous K₃PO₄ at 82 °C under nitrogen overpressure of 0.3 bar yields the corresponding 2-(4-fluorophenyl)thiazole-5-carboxylate. The bromide functions as a privileged orthogonal handle while the methyl ester remains intact, enabling downstream diversification without protective group manipulation. On a 500 L glass-lined reactor equipped with a retreat-curve impeller, the heterogeneous mixture demands vigorous agitation at a tip speed of 1.8 m/s to prevent palladium black agglomeration; failure to maintain this shear regime results in instantaneous catalyst deactivation and a batch yield drop from 82% to below 35%. Post-reaction workup follows a strictly sequential protocol: organic phase separation at 55 °C, adsorption on activated charcoal (Darco G-60, 2 wt% relative to crude), filtration through a 0.45 µm polypropylene cartridge at 20 psi differential pressure, and vacuum distillation to ≤5 mbar. Palladium residue measured by ICP-MS per USP <232> must not exceed 8 ppm for APIs intended for parenteral administration; otherwise a secondary extraction with 5% aqueous N-acetyl-L-cysteine at pH 5.2 is implemented. The isolated product, a pale yellow crystalline solid of 99.3% HPLC area purity (C18, 254 nm), serves as the core building block for Type II kinase inhibitors targeting the DFG-out conformation, where the biaryl geometry directly influences the ligand’s residence time at the ATP-binding pocket.

What Limits Buchwald–Hartwig Amination Throughput on a Pilot Scale?

Coupling methyl 2-bromothiazole-5-carboxylate with 2,6-diisopropylaniline in toluene at 105 °C proceeds through a catalytic resting state dominated by Pd(0) ligation to XPhos, provided the water content of the solvent lot stays below 80 ppm by Karl Fischer titration. The pre-activation step demands separate dissolution of Pd₂(dba)₃ (0.45 mol%) and XPhos (1.35 mol%) in deoxygenated toluene stirred at 40 °C for 45 minutes under argon; skipping this lag phase generates palladacycle intermediates that retard the oxidative addition rate by a factor of 7. When the reaction mass is transferred to a 2000 L Hastelloy C-276 autoclave, the exotherm onset reaches ±1.8 °C/min above 80 °C, requiring jacket cooling modulation with a PID loop tuned to a 0.3 °C overshoot tolerance to avoid dehalogenation of the thiazole ring. Post-reaction, removal of inorganic salts is achieved by tangential flow filtration through a 0.2 µm ceramic membrane; retentate recycling at 1.5 bar transmembrane pressure concentrates the palladium species, which are subsequently scrubbed with a silica-bound thiol resin (QuadraSil AP) at a residence time of 18 minutes in a fixed-bed column. Residual Pd drops from 320 ppm to 2.7 ppm, meeting the oral drug substance limit of 10 ppm per ICH Q3D Option 2. The resultant N-aryl thiazole ester shows a melting endotherm at 137.2 °C (DSC, 10 K/min) and is employed in the GMP synthesis of a non-nucleoside reverse transcriptase inhibitor, where any batch-to-batch variance in the N–Ar rotamer population—audited by VT-NMR at −40 °C—must stay below 3% relative area to satisfy bioequivalence criteria.

Agrochemical Active Ingredient Precursor: Methoxy-Directed Ortho-Lithiation Pathway

Methyl 2-bromothiazole-5-carboxylate undergoes lithium-bromine exchange with n-butyllithium (1.02 eq, 2.5 M in hexane) in anhydrous THF at −72 °C to generate the 2-lithiothiazole intermediate, which is trapped by elemental sulfur (S₈, 1.05 eq) introduced as a dry powder through a glovebox-port hopper. The temperature window is exceptionally narrow: at −65 °C, the lithiated species attacks the ester carbonyl with a rate constant of 0.12 min⁻¹, and at −78 °C the exchange kinetics slow beyond acceptable cycle time for a 150 kg batch. Cryogenic jacketed vessels rated for −80 °C with silicone oil circulation (Huber Unistat 905) maintain the setpoint within ±1.2 °C; any excursion beyond −68 °C triggers an automatic quench with isopropanol to pre-empt the ketone side product. The resulting thiolate is alkylated by 1-chloro-3-iodopropane (1.15 eq) at −20 °C, and the intermediate is transformed into a thiazole-sulfide fungicide lead via sequential oxidation with 30% H₂O₂ in acetic anhydride at 0 °C. The process stream is dried by azeotropic distillation with toluene (45 mbar, 38 °C) to ≤0.2 wt% moisture prior to the final SNAr on a pyrimidine ring. Residual lithium salts determined by flame photometry must fall below 15 µg/g to avoid phytotoxicity in glasshouse screening. Compliance with CIPAC MT 46.3 for suspension concentratability and accelerated storage stability at 54 °C for 14 days (OECD 111) is verified before formulation trials.

Direct arylation polymerization (DArP) employing methyl 2-bromothiazole-5-carboxylate as an electron-deficient A-unit with 2,2′-bithiophene as D-unit proceeds through a concerted metalation-deprotonation mechanism mediated by Pd(OAc)₂ (2.5 mol%), PCy₃·HBF₄ (5 mol%), pivalic acid (30 mol%), and K₂CO₃ (2.3 eq) in DMAc at 120 °C for 36 h under sealed-tube conditions. Monomer purity is strictly specified: the bromothiazole monomer must exhibit a single endothermic peak by DSC (41.5 °C onset) and ≤50 ppm each of Fe, Ni, and Cu by ICP-OES, as these metals coordinate to the thiazole nitrogen and quench the propagating chain. After precipitation into methanol/water 9:1, the crude polymer is subjected to sequential Soxhlet extraction with acetone, hexane, and chloroform; the number-average molecular weight (Mₙ) of the chloroform fraction, measured by high-temperature GPC at 150 °C in 1,2,4-trichlorobenzene against polystyrene standards, must reach at least 28 kDa with a Đ of ≤1.35 to ensure continuous film morphology in slot-die coating. Thin-film transistors fabricated on octadecyltrichlorosilane-treated SiO₂/Si substrates under N₂ in a glovebox (<0.1 ppm O₂, <0.1 ppm H₂O) display saturated field-effect electron mobilities of 0.15–0.21 cm²/V·s when measured according to the transfer length method (TLM) with channel lengths of 20 µm. In non-fullerene organic photovoltaic blends processed from o-xylene at 85 °C, the fluorinated analogue of this acceptor polymer retains 92% of initial power conversion efficiency after 500 h under AM 1.5G illumination at 65 °C ambient, as per ISOS-L-2 testing protocol.

Can Residual Bromide and Palladium Artifacts Distort Biological Screening Data in Early Drug Discovery?

When methyl 2-bromothiazole-5-carboxylate is employed as the starting material in parallel synthesis libraries aimed at kinome-wide selectivity profiling, incomplete removal of trace Pd and Br-bearing by-products leads to false-positive inhibition in ATPase-coupled luciferase assays. The bromide ion at concentrations as low as 50 nM competes with the luciferin substrate for the enzyme’s oxyanion pocket, causing apparent IC₅₀ shifts of up to 100-fold for hits with genuine target engagement below 500 nM. Consequently, every library compound generated through Suzuki or Stille sequences from this intermediate must undergo rigorous purification by mass-directed preparative HPLC (C18, ACN/water with 0.01% TFA) followed by a scavenging step: a 15-minute incubation with QuadraSil TA resin (50 mg/mL) in THF at 22 °C. The residual palladium content, verified by triple-quadrupole ICP-MS with a method detection limit of 0.1 ppb, must register below 0.5 ppm for any compound submitted to enzymatic assays. Furthermore, the methyl ester itself is not metabolically stable in the presence of mouse liver microsomes (t₁/₂ 12 min), and rapid saponification by carboxylesterase Ce1d alters the compound’s logD₇.₄ from 2.4 to 0.9 within 30 minutes of incubation; SAR teams are advised to convert the ester to the corresponding isopropyl or cyclopropyl ester if preliminary pharmacokinetic profiling is contemplated. Stability data should be generated per EBF recommendations using an LC-HRMS platform monitoring the [M+H]⁺ ion at 70,000 resolution (FWHM) over a 4-hour time course.

2-Bromothiazole-5-carboxylic acid, obtained by cold saponification of the methyl ester with LiOH·H₂O (1.05 eq) in THF/water 3:1 at 0 °C to 5 °C, is activated with HATU (1.1 eq) and DIPEA (2.5 eq) in DMF for 8 minutes and then coupled to a Wang-resin-bound dipeptide in a CEM Liberty Blue microwave synthesizer. The coupling cycle runs at 50 °C with 50 W of microwave power for 10 minutes, and the bromine handle remains intact, confirmed by on-resin C–H bending modes at 1060 cm⁻¹ in ATR-FTIR. After global cleavage with TFA/TIS/H₂O 95:2.5:2.5, the crude peptide thiazole is purified by RP-HPLC with a gradient of 20–55% ACN over 25 minutes; the target peak at 214 nm typically accounts for 88–91% of total integrated area. A key incompatibility arises with Asp-Gly sequences: the α-carboxamide of the thiazole accelerates background epimerization at the aspartate residue (D/L ratio shift from 0.8% to 4.6% when the coupling mixture is held beyond 15 minutes), so immediate resin wash and cold ether precipitation are mandatory. The resulting bromothiazole-containing linear peptide serves as a substrate for intramolecular Ullmann cyclization to construct bicyclic azapeptide mimetics that inhibit the SARS-CoV-2 Mᵖʳᵒ homodimer with Kᵢ values in the low nanomolar range; biological testing is performed in accordance with the FRET-based enzymatic assay protocol described in OECD Guidance Document 34 and requires a peptide purity threshold of ≥96% (analytical HPLC, C8, 0.1% TFA modifier) and residual copper quantified by ICP-OES at less than 8 ppm.

Ortho-Substitution–Driven Diastereoselective Quaternization in Spirocyclic Scaffold Assembly

The steric and electronic profile of methyl 2-bromothiazole-5-carboxylate allows diastereoselective alkylation of the thiazole nitrogen with (R)-glycidyl nosylate in nitromethane at 40 °C, generating a chiral thiazolium salt with a diastereomeric excess of 94% (Chiralpak IC, hexane/EtOH 60:40, 1.0 mL/min). The bromide substituent polarizes the π-system sufficiently to direct the nucleophilic attack through the Re face of the oxirane, as supported by DFT calculations at the M06-2X/6-31+G(d,p) level. After quaternization, the intermediate undergoes an intramolecular aldol condensation upon treatment with LDA (2.2 eq) at −40 °C in THF, forming a spirocyclic oxazolidine-thiazoline hybrid. On a 20 L scale, the cyclization exhibits a critical induction time of 18–22 minutes; premature addition of water quench before the deep-red solution turns amber results in an uncyclized linear by-product that co-elutes with the target during normal-phase chromatography (SiO₂, EtOAc/hexane 1:3). The crystalline spiro compound isolated after slurry wash with MTBE at −10 °C shows a single-crystal X-ray structure confirming the (S) configuration at the spiro center, and its optical rotation [α]²⁰D of +118° (c 1.0, CHCl₃) serves as the identity release specification. This spirocyclic building block is an advanced intermediate en route to a class of FXIIa coagulation factor inhibitors, wherein the bromine is displaced by a 4-aminopyrazole substituent under microwave heating at 135 °C for 45 minutes, and the drug substance purity is controlled to 99.5% by qNMR using maleic acid as internal standard, consistent with the requirements of Ph. Eur. 2.2.33.